Clinical trials: Glomerular Diseases
Glomerular Disease, Proteinuria
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
- Trial name
- NCT04939116
- Testing
- ANG-3070
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Angion Biomedica Corp
C3G
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol.
- Trial name
- APPEAR-C3G (NCT04817618)
- Testing
- iptacopan
- Where
- 87 sites in United States, Argentina and 17 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Diabetes, Hypertensive Disease
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
Diabetes is the leading cause of chronic kidney disease in developed countries. About 30-40% of patients with type 1 and type 2 diabetes mellitus will develop diabetic nephropathy.
- Trial name
- eGFR (NCT01500590)
- Testing
- Renin-angiotensin system blockers, non-renin angiotensin system blockers
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Hospital Authority, Hong Kong
C3 Glomerulonephritis, C3 Glomerulopathy
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.
- Conditions
- C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN
- Trial name
- NCT03459443
- Testing
- Danicopan
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 22 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Diabetes
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty…
- Trial name
- VITAL-DKD (NCT01684722)
- Testing
- Vitamin D, Omega-3 fatty acids (fish oil)
- Where
- United States
- Volunteers
- 1,312 people
- Sponsor
- University of Washington
Treatment
Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy
The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.
- Trial name
- NCT00302510
- Testing
- immunoadsorption
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Obesity, Glomerulopathy
Dietary Intervention in Obesity-related Glomerulopathy
Obesity-related glomerulopathy (ORG) is a silent comorbidity associated with obesity whose incidence is increasing in parallel to the obesity epidemic.
- Trial name
- ORG-VLCD-2022 (NCT05294770)
- Testing
- Optisource® Plus: Very Low Calorie Diet treatment, Hypocaloric Mediterranean Diet
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud